Search Results - kirk+gustafson

3 Results

Sort By:

Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors

Abstract: Hypoxia is a characteristic of many solid tumors resulting from accelerated cellular proliferation and inadequate vascularization. HIF-1 is a transcription factor critical for maintaining cellular homeostasis in, and adaptively responding to, low oxygen environments. HIF-1 becomes activated through binding to the transcriptional co-activator...

Published: 4/8/2024 | Inventor(s): Kirk Gustafson, Martin Schnermann, Susanna Chan, Paresma Patel, William Figg, James McMahon

Keywords(s): CANCER, Hypoxia Inhibitor, Malaria, small molecule

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues

Abstract: Topoisomerase enzymes play an important role in cancer progression by controlling changes in DNA structure through catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle. Therefore, topoisomerases are important targets for cancer chemotherapy. Many topoisomerase 1 (TOP1) inhibitors...

Published: 4/8/2024 | Inventor(s): Barry O'Keefe, Lauren Krumpe, Johan Rosengren, Ingrid Schroeder, Alan Bermingham, Christophe Marchand, Kirk Gustafson, Brice Wilson, Yves Pommier

Keywords(s): CANCER, Chemosensitizing Agents, CHEMOTHERAPY, Cyclic Peptide, Irinotecan TOP1, O’Keefe, Recifin, Tdp1, Topoisomerase 1 inhibitors, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 Inhibitors

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics

Use of Cucurbitacins and Withanolides for the Treatment of Cancer

Abstract: Certain members of the cucurbitacin and Withanolide family have been identified that can sensitize some tumor cell lines to cell death (apoptosis) on subsequent exposure of the cells to pro-apoptotic receptor agonists (PARAS) of the TRAIL "death receptors". These PARAS include TRAIL itself, and agonist antibodies to two of its receptors death...

Published: 5/22/2024 | Inventor(s): Thomas Sayers, Kirk Gustafson, Karen Erickson, Alan Brooks, Curtis Henrich, Nancy Booth

Keywords(s): cucurbitacin, Immunotherapy, mapatumamab, TRAIL, withanolide

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing